NanoViricides, Inc. (NYSE American: NNVC) has underscored the potential need for broad-spectrum antiviral treatments in the wake of the recent Andes hantavirus incident aboard a cruise ship. The company highlighted its clinical-stage antiviral candidate, NV-387, as a therapeutic platform that could address emerging viral threats, including hantaviruses.
NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers, with no adverse events reported. The drug has demonstrated effectiveness in animal models against multiple viral lung infections, including coronaviruses, respiratory syncytial virus (RSV), influenza, monkeypox, and measles. This broad-spectrum activity positions NV-387 as a potential countermeasure against a wide range of pathogenic viruses, according to the company.
The Andes hantavirus incident, which occurred on a cruise ship, highlights the vulnerability of global travel to novel viral outbreaks. Hantaviruses, which are typically transmitted through rodent droppings, can cause severe respiratory illness in humans. The current lack of approved antiviral treatments for hantavirus infections underscores the urgency for developing broad-spectrum antiviral drugs like NV-387.
NanoViricides is focused on advancing NV-387 into Phase II human clinical trials. The company’s lead drug candidate is designed to treat respiratory viral infections, including COVID-19, Long COVID, and influenza. Additionally, NV-387 has shown efficacy in animal models for monkeypox, smallpox, and measles, indicating its potential beyond respiratory viruses.
The company’s other advanced drug candidate, NV-HHV-1, targets herpesvirus infections, including HSV-1, HSV-2, and varicella-zoster virus. However, NanoViricides cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to reliance on external collaborators and consultants.
The announcement comes as the global health community continues to grapple with emerging infectious diseases. The COVID-19 pandemic demonstrated the devastating impact of a novel virus, and experts warn that future pandemics are likely. Broad-spectrum antivirals like NV-387 could be crucial in providing early treatment options before specific vaccines or therapies are developed.
For more information about NanoViricides and its pipeline, visit the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/OYkof.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship.